Compare Paychex, Inc. (PAYX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Paychex, Inc. trades at $103.98 (market cap $37.19B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Paychex, Inc. is far larger — about 3.7× State Street SPDR S&P Biotech ETF's market cap, and Paychex, Inc. pays a 4.56% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PAYX | XBI | |
|---|---|---|
Market Cap | $37.19B | $10.11B |
Volume | 3,344,316 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $128.59 | $169.55 |
52-Week Low | $85.57 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $40.87B | — |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.46, up 2.87% on the day, showing resilience after recent volatility. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages, while fundamentals remain solid with consistent earnings beats, a 27.35% net income margin, and a forward P/E of 20.73. Recent news highlights strong Q1 2027 results but also concerns over dividend sustainability and labor market exposure.
The outlook is cautiously optimistic, supported by robust profitability and a consensus price target of $111, offering potential upside. Key risks include sensitivity to small business employment trends, high valuation multiples, and investor scrutiny of cash flow allocation. The stock presents a hold case for income-focused investors, balancing dividend yield against growth deceleration concerns.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
